Working… Menu

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00012246
Recruitment Status : Terminated (Administratively Terminated)
First Posted : January 27, 2003
Last Update Posted : May 16, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
The University of Texas Medical Branch, Galveston

Brief Summary:

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the gastrointestinal tract.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Esophageal Cancer Extrahepatic Bile Duct Cancer Gallbladder Cancer Gastric Cancer Pancreatic Cancer Small Intestine Cancer Biological: carcinoembryonic antigen peptide 1-6D Biological: incomplete Freund's adjuvant Biological: sargramostim Phase 2

Detailed Description:


  • Determine whether immunization with carcinoembryonic antigen (CEA) peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant or dissolved in sargramostim (GM-CSF) can generate CAP 1-6D-specific T cells in patients with CEA-producing adenocarcinomas of gastrointestinal tract origin.
  • Determine whether vaccination with CAP 1-6D can generate cytotoxic T cells against CEA-expressing tumors in these patients.
  • Determine whether this vaccine can produce antitumor responses in these patients.
  • Determine the frequency and severity of toxic effects associated with this vaccine in these patients.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1.
  • Arm II: Patients receive CAP 1-6D dissolved in sargramostim (GM-CSF) intradermally on day 1.

Treatment repeats in both arms every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 3 weeks and then as necessary.

PROJECTED ACCRUAL: A total of 10-36 patients (5-18 per arm) will be accrued for this study within 36 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin
Study Start Date : July 2002
Actual Primary Completion Date : July 2006
Actual Study Completion Date : July 2006

Primary Outcome Measures :
  1. Production of CAP 1-6D T cells
  2. Production of cytotoxic T cells
  3. Antitumor response
  4. Frequency and severity of toxic effects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed stage II, III, or IV adenocarcinoma of the gastrointestinal tract originating in 1 of the following:

    • Esophagus
    • Stomach
    • Pancreas
    • Small intestine
    • Colon or rectum
    • Gall bladder
    • Extrahepatic bile ducts
    • Ampulla of Vater
  • Completed standard therapy and at risk of recurrent disease OR has relatively stable metastatic disease and a life expectancy of at least 6 months
  • Carcinoembryonic antigen (CEA)-producing tumor as evidenced by detectable blood levels of CEA or positive for CEA on immunohistochemical staining
  • Human Leukocyte Antigen (HLA)-A2+



  • 18 and over

Performance status:

  • Southwest Oncology Group (SWOG) 0-1

Life expectancy:

  • See Disease Characteristics


  • White Blood Count (WBC) at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 8 g/dL


  • Serum Glutamic Oxalacetic Transaminase (SGOT) or Serum Glutamic Pyruvic Transaminase (SGPT) no greater than 3 times upper limit of normal
  • Hepatitis B and C negative


  • Creatinine no greater than 2.0 mg/dL


  • No other prior malignancy unless currently disease free and off all therapy for that malignancy

    • Early skin cancer allowed
  • No AIDS
  • HIV negative
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for 30 days after study participation


Biologic therapy:

  • At least 4 weeks since prior immunotherapy


  • At least 4 weeks since prior chemotherapy

Endocrine therapy:

  • Not specified


  • At least 4 weeks since prior radiotherapy


  • At least 4 weeks since prior surgery


  • No other concurrent therapy for malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00012246

Layout table for location information
United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555-0209
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Robert P. Whitehead, MD University of Texas
Layout table for additonal information
Responsible Party: The University of Texas Medical Branch, Galveston Identifier: NCT00012246    
Other Study ID Numbers: CDR0000068497
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: May 16, 2013
Last Verified: May 2013
Keywords provided by The University of Texas Medical Branch, Galveston:
stage II colon cancer
stage III colon cancer
stage IV colon cancer
stage II gastric cancer
stage III gastric cancer
stage IV gastric cancer
recurrent gastric cancer
stage II pancreatic cancer
stage III pancreatic cancer
recurrent pancreatic cancer
stage II rectal cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
stage II esophageal cancer
stage III esophageal cancer
stage IV esophageal cancer
recurrent esophageal cancer
adenocarcinoma of the stomach
small intestine adenocarcinoma
localized gallbladder cancer
unresectable gallbladder cancer
recurrent gallbladder cancer
localized extrahepatic bile duct cancer
unresectable extrahepatic bile duct cancer
recurrent extrahepatic bile duct cancer
recurrent small intestine cancer
adenocarcinoma of the esophagus
adenocarcinoma of the colon
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Stomach Neoplasms
Esophageal Neoplasms
Gallbladder Neoplasms
Bile Duct Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Biliary Tract Neoplasms
Biliary Tract Diseases
Gallbladder Diseases
Bile Duct Diseases
Freund's Adjuvant